Efficacy and safety of the addition of sitagliptin to treatment of youth with type 2 diabetes and inadequate glycemic control on metformin without or with insulin.

导出 LinkOut

翻译打印收藏纠错

作者： Muhammad Yazid,Jalaludin ^[1] ; Asma,Deeb ^[2] ; Philip,Zeitler ^[3] ; Raymundo,Garcia ^[4] ; Ron S,Newfield ^[5] ; Yulia,Samoilova ^[6] ; Carmen A,Rosario ^[7] ; Naim,Shehadeh ^[8] ; Chandan K,Saha ^[9] ; Yilong,Zhang ^[10] ; Martina,Zilli ^[10] ; Lynn W,Scherer ^[10] ; Raymond L H,Lam ^[10] ; Gregory T,Golm ^[10] ; Samuel S,Engel ^[10] ; Keith D,Kaufman ^[10] ; R Ravi,Shankar ^[10]

作者单位： Department of Paediatrics, Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia. ^[1] Department of Pediatric Endocrinology, Sheikh Shakhbout Medical City, Abu Dhabi, United Arab Emirates. ^[2] Department of Endocrinology, Children's Hospital Colorado Clinical, University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA. ^[3] Department of Internal Medicine and Clinical Endocrinology, Centro de Estudios Clínicos y Especialidades Medicas (CECEM), Nuevo Leon, Mexico. ^[4] Department of Pediatric Endocrinology, Rady Children's Hospital, University of California San Diego, San Diego, California, USA. ^[5] Department of Pediatric Endocrinology and Diabetology, Siberian State Medical University, Tomsk, Russia. ^[6] Department of Pediatric Endocrinology, Hospital General Plaza de la Salud, Santo Domingo, Dominican Republic. ^[7] Department of Pediatrics A and the Pediatric Diabetes Unit, Institute of Diabetes, Endocrinology, and Metabolism, Rambam Medical Center, Haifa, Israel. ^[8] Department of Biostatistics, Indiana University School of Medicine, Indianapolis, Indiana, USA. ^[9] Merck Research Laboratories, Merck & Co., Inc, Kenilworth, New Jersey, USA. ^[10]

关键词 DPP-4 MK-0431 antihyperglycemic agents dipeptidyl peptidase-4 inhibitor incretin pediatric youth-onset type 2 diabetes